

## ORYZON to present at the Neuroscience Innovation Forum in San Francisco

**The company will also participate at the Trout Annual 1x1 Management Access Event 2018 during the week of the JP Morgan Healthcare Conference**

**MADRID, SPAIN and CAMBRIDGE, MA, January 4, 2018** – Oryzon Genomics (ISIN Code: ES0167733015, ORY), a public clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, has announced today that Dr. Carlos Buesa and Dr. Roger Bullock, Oryzon's CEO and CMO, will present the recent progresses of ORY-2001 at the Neuroscience Innovation Forum for BD&L and Investment in Therapeutics and Technology to take place at the Marines' Memorial Club, San Francisco on the 7th of January 2018, a day before the JP Morgan meeting. Dr. Buesa will also participate as a panelist in a round table entitled "Advances in Alzheimer's and other Cognitive Disorders".

Every January in San Francisco, the JP Morgan Healthcare Conference brings together industry leaders, financial sponsors and investors to explore innovation and market trends in the pharmaceutical industry. This week attracts additional parallel conferences and multilateral activities between all actors in the industry in a week that is widely viewed as setting the tone for the coming year. One example is this specialized Neuroscience Innovation Forum that covers BioPartnering for CNS, with industry keynotes and panels on AD, PD, Neuropsychiatry and Pain Management.

Oryzon will also participate at the Trout Annual 1x1 Management Access Event 2018 during the whole week of the JP Morgan and the CEO and CMO will hold meetings with institutional investors, analysts and other members of the biotech community at the Handlery Hotel at Union Square.

The company has recently reported in several scientific conferences that ORY-2001 exerts a holistic action in the different alterations seen in patients suffering from AD and other neurodegenerative disorders. Different experiments suggest that ORY-2001 acts as a disease modifying drug. In AD patients and other neurodegenerative disorders, cognitive deterioration is often accompanied by episodes of agitation, aggression, psychosis, apathy and depression. In preclinical studies, ORY-2001 not only restores memory but reduces the exacerbated aggressiveness of SAMP8 mice to normal levels and also reduces social avoidance in rat models maintained in isolation. After proving safety in the 9 month preclinical regulatory tox studies, ORY-2001 demonstrated safety and tolerability in a Phase I clinical trial conducted with 106 healthy volunteers that allowed to establish the doses for Phase II in patients. The company recently received the approval to carry out a Phase IIA with ORY-2001 in patients with multiple sclerosis (MS) and plans to request soon the corresponding authorizations for a Phase IIA clinical trial in patients with Alzheimer's disease.

ORY-2001 is an oral and brain penetrant drug that selectively inhibits LSD1 and MAOB. The molecule acts on several levels, reduces cognitive impairment, memory loss and neuroinflammation, and at the same time has neuroprotective effects. In several preclinical models of MS, ORY-2001 exhibits strong

and durable efficacy. LSD1 is an epigenetic modulator, which regulates histone methylation and modulates gene expression patterns. Epigenetic approaches to modify the progression of various neurodegenerative diseases, which focus on the production of changes in gene expression patterns in brain cells, have generated interest in the pharmaceutical industry.

### **About Oryzon**

Founded in 2000 in Barcelona, Spain, Oryzon (ISIN Code: ES0167733015) is a clinical stage biopharmaceutical company considered as the European champion in Epigenetics. The company has one of the strongest portfolios in the field. Oryzon's LSD1 program has resulted in + 20 patent families and has rendered two compounds in clinical trials. In addition, Oryzon has ongoing programs for developing inhibitors against other epigenetic targets. The company has a strong technological platform for biomarker identification and performs biomarker and target validation for a variety of malignant and neurodegenerative diseases. Oryzon's strategy is to develop first in class compounds against novel epigenetic targets through Phase II clinical trials, at which point it is decided on a case by-case basis to either keep the development in-house or to partner or outlicense the compound for late stage development and commercialization. The company has offices in Spain and USA. For more information, visit [www.oryzon.com](http://www.oryzon.com).

### **FORWARD-LOOKING STATEMENTS**

This communication contains forward-looking information and statements about Oryzon Genomics, S.A., including financial projections and estimates and their underlying assumptions, statements regarding plans, objectives and expectations with respect to future operations, capital expenditures, synergies, products and services, and statements regarding future performance. Forward-looking statements are statements that are not historical facts and are generally identified by the words "expects", "anticipates", "believes", "intends", "estimates" and similar expressions. Although Oryzon Genomics, S.A. believes that the expectations reflected in such forward-looking statements are reasonable, investors and holders of Oryzon Genomics, S.A. shares are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Oryzon Genomics, S.A., that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include those discussed or identified in the documents sent by Oryzon Genomics, S.A. to the *Comisión Nacional del Mercado de Valores*, which are accessible to the public. Forward-looking statements are not guarantees of future performance. The auditors of Oryzon Genomics, S.A. have not reviewed them. You are cautioned not to place undue reliance on the forward-looking statements, which speak only as of the date they were made. All subsequent oral or written forward-looking statements attributable to Oryzon Genomics, S.A. or any of its members, directors, officers, employees or any persons acting on its behalf are expressly qualified in their entirety by the cautionary statement above. All forward-looking statements included herein are based on information available to Oryzon Genomics, S.A. on the date hereof. Except as required by applicable law, Oryzon Genomics, S.A. does not undertake any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. This press release is not an offer of securities for sale in the United States. The Company's securities may not be offered or sold in the United States absent registration or an exemption from registration. Any public offering of the Company's securities to be made in the United States will be made by means of a prospectus that may be obtained from the Company or the selling security holder, as applicable, that will contain detailed information about the Company and management, as well as financial statements.

#### **US Contact:**

**The Trout Group**

**Thomas Hoffmann**

+1 646 378 2932

[thoffmann@troutgroup.com](mailto:thoffmann@troutgroup.com)

#### **Spain:**

**ATREVIA**

**Patricia Cobo/Luis Rejano**

+34 91 564 07 25

[pcobo@atrevia.com](mailto:pcobo@atrevia.com)

[lrejano@atrevia.com](mailto:lrejano@atrevia.com)

#### **The Company:**

**Emili Torrell**

**BD Director**

+34 93 515 13 13

[etorrell@oryzon.com](mailto:etorrell@oryzon.com)